Catalyst Wire Dossier Catalyst Wire Dossier

emibetuzumab

emibetuzumab · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for emibetuzumab, covering 2018-06-25 to 2020-12-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer [Phase 1, Phase 2]

See pricing